Tumor-In fi ltrating Lymphocytes and Prognosis : A Pooled Individual Patient Analysis of Early-Stage Triple-Negative Breast Cancers

Sherene Loi, MD; Damien Drubay, PhD; Sylvia Adams, MD; Giancarlo Pruneri, MD; Prudence A. Francis, MD; Magali Lacroix-Triki, MD; Heikki Joensuu, MD; Maria Vittoria Dieci, MD; Sunil Badve, MD; Sandra Demaria, MD; Robert Gray, PhD; Elisabetta Munzone, MD; Jerome Lemonnier, PhD; Christos Sotiriou, MD; Martine J. Piccart, MD; Pirkko-Liisa Kellokumpu-Lehtinen, MD; Andrea Vingiani, MD; Kathryn Gray, PhD; Fabrice Andre, MD; Carsten Denkert, MD; Roberto Salgado, MD; and Stefan Michiels, PhD

[1]  Peter Schmid,et al.  LBA13Relationship between tumor infiltrating lymphocyte (TIL) levels and response to pembrolizumab (pembro) in metastatic triple-negative breast cancer (mTNBC): Results from KEYNOTE-086 , 2017 .

[2]  C. Perou,et al.  Combined immune checkpoint blockade as a therapeutic strategy for BRCA1-mutated breast cancer , 2017, Science Translational Medicine.

[3]  Krishna R. Kalari,et al.  Impact of histopathology, tumor-infiltrating lymphocytes, and adjuvant chemotherapy on prognosis of triple-negative breast cancer , 2017, Breast Cancer Research and Treatment.

[4]  J. Luke,et al.  Density of immunogenic antigens does not explain the presence or absence of the T-cell–inflamed tumor microenvironment in melanoma , 2016, Proceedings of the National Academy of Sciences.

[5]  Carsten Denkert,et al.  Standardized evaluation of tumor-infiltrating lymphocytes in breast cancer: results of the ring studies of the international immuno-oncology biomarker working group , 2016, Modern Pathology.

[6]  R. Gelber,et al.  Tumor-infiltrating lymphocytes (TILs) are a powerful prognostic marker in patients with triple-negative breast cancer enrolled in the IBCSG phase III randomized clinical trial 22-00 , 2016, Breast Cancer Research and Treatment.

[7]  Richard D Riley,et al.  External validation of clinical prediction models using big datasets from e-health records or IPD meta-analysis: opportunities and challenges , 2016, BMJ.

[8]  L. Zitvogel,et al.  Microbiome and Anticancer Immunosurveillance , 2016, Cell.

[9]  Carsten Denkert,et al.  Clinical relevance of host immunity in breast cancer: from TILs to the clinic , 2016, Nature Reviews Clinical Oncology.

[10]  G Pruneri,et al.  Clinical validity of tumor-infiltrating lymphocytes analysis in patients with triple-negative breast cancer. , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

[11]  H. Wildiers,et al.  Guidelines for time-to-event end point definitions in breast cancer trials: results of the DATECAN initiative (Definition for the Assessment of Time-to-event Endpoints in CANcer trials). , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

[12]  Virginia G Kaklamani,et al.  Prospective Validation of a 21-Gene Expression Assay in Breast Cancer. , 2015, The New England journal of medicine.

[13]  M. Mathieu,et al.  Prognostic and predictive value of tumor-infiltrating lymphocytes in two phase III randomized adjuvant breast cancer trials. , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

[14]  T. Schumacher,et al.  Neoantigens in cancer immunotherapy , 2015, Science.

[15]  Carsten Denkert,et al.  Tumor-infiltrating lymphocytes and response to neoadjuvant chemotherapy with or without carboplatin in human epidermal growth factor receptor 2-positive and triple-negative primary breast cancers. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  T. Nielsen,et al.  The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014. , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

[17]  Ying Wang,et al.  STING-dependent cytosolic DNA sensing mediates innate immune recognition of immunogenic tumors. , 2014, Immunity.

[18]  Molin Wang,et al.  Prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancers from two phase III randomized adjuvant breast cancer trials: ECOG 2197 and ECOG 1199. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  F M Blows,et al.  Association between CD8+ T-cell infiltration and breast cancer survival in 12,439 patients. , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

[20]  S Michiels,et al.  Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial. , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

[21]  Stefan Michiels,et al.  Prognostic and predictive value of tumor-infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy: BIG 02-98. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  Laura J. Esserman,et al.  Leukocyte composition of human breast cancer , 2011, Proceedings of the National Academy of Sciences.

[23]  L. Mauriac,et al.  Five-Year Analysis of the FNCLCC-PACS04 Trial: FEC100 vs ED75 for the Adjuvant Treatment of Node Positive Breast Cancer. , 2009 .

[24]  Xueri Li,et al.  Sequential Adjuvant Epirubicin-Based and Docetaxel Chemotherapy for Node-Positive Breast Cancer Patients:The FNCLCC PACS 01 Trial , 2009 .

[25]  Tianxi Cai,et al.  Evaluating Prediction Rules for t-Year Survivors With Censored Regression Models , 2007 .